Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis

Renal Failure

Volumn 30, Issue 6, 2008, Pages 603-609

  Demircin, Gülay ^a   Öner, Ayşe ^b   Erdoǧan, Özlem ^a   Delibaş, Ali ^c   Baysun, Şahika ^a   Bülbül, Mehmet ^a   Bek, Kenan ^d   Oksal, Ayşegül ^a  

^a DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^b UFUK UNIVERSITY   (Turkey)

^c MERSIN UNIVERSITY   (Turkey)

^d ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Childhood; Clinical findings; Diffuse proliferative lupus nephritis; Prognosis; Quadruple therapy

Indexed keywords

AZATHIOPRINE; CALCIUM; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TUBERCULOSTATIC AGENT; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; ASEPTIC NECROSIS; CHILD; CHILDHOOD; CLINICAL ARTICLE; CLINICAL FEATURE; CUSHINGOID SYNDROME; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LEUKOPENIA; LUNG TUBERCULOSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MORBIDITY; NEPHROTIC SYNDROME; OSTEOPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZATHIOPRINE; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; PROBABILITY; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 48149109278     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802132171     Document Type: Article

References (40)

1. th ed. Philadelphia: Elsevier Saunders; 2005:342-391.
2. Gitelman MK, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin N Am. 2002;28:561-577.
3. th ed. Philadelphia: Lippincott Williams & Wilkins, 2004:865-886.
4. Kashgarian M. Lupus nephritis: Lessons from the path lab (Nephrology forum). Kidney Int. 1994;45:928-938.
5. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol. 2000;14:158-166.
6. Boumpas DT. Lupus nephritis. Nephrol Dial Transplant. 2001;16 (Suppl. 6):55-57.
7. Tan EM, Cohen AS, Fies JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
8. nd ed. New York: Oxford University Press; 1998:935-959.
9. Austin HA, Klippel JH, Balow JE, Leriche NG, Steinberg AG. Therapy of lupus nephritis. N Engl J Med. 1986;314:614-619.
10. Erdoǧan Ö, Öner A, Demircin G, et al. A boy with consecutive development of SLE and Wegener granulomatosis. Pediatr Nephrol. 2004;19:438-441.
11. Bogdanovic R, Nikolic V, Pasic S, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol. 2004;19:36-44.
12. Zappitelli M, Duffy C, Bernard C, et al. Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol. 2004;19:503-510.
13. Dixit MP, Bracamonte E, Dixit N. Intravenous cyclophosphamide-resistant systemic lupus erythematosus in Arizona. Pediatr Nephrol. 2004;19:738-743.
14. Wright EC, Tullus K, Dillon MJ. Retrospective study of plasma exchange in children with systemic lupus erythematosus. Pediatr Nephrol. 2004;19:1108-1114.
15. nd ed. Boston: Little Brown and Company; 1992:1407-1465.
16. Crespo MRG, Fernandez JIL, Usera G, Poveda MJ, Reino JJG. Outcome of silent lupus nephritis. Semin Arthritis Rheum. 1996;26:468-476.
17. Kuiper-Geertsma DG, Derksen RHWM. Newer drugs for the treatment of lupus nephritis. Drugs. 2003;63:167-180.
18. Hebert LA. Management of lupus nephropathy. Nephron Clin Pract. 2003;93:c7-c12.
19. Ioannidis JPA, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57:258-264.
20. Hernandez JC, Ros JO, Labrador M, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methyl prednisolone. Lupus. 2003;12:287-296.
21. Barbano G, Gusmano R, Damasio B, et al. Childhood onset lupus nephritis: A single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol. 2002;15:123-129.
22. Hejaili FF, Moist LM, Clark WF. Treatment of lupus nephritis. Drugs. 2003;63:257-274.
23. Lehman TJA, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis. 2004;63:321-323.
24. Suzuki K, Tanaka H, Tsugawa K, Ito E. Effective treatment with cyclosporine A of a child with systemic lupus erythematosus resistant to cyclophosphamide pulse therapy. Thoku J Exp Med. 2006;208:355-359.
25. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis. 1998;32:318-322.
26. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis. 1997;56:690-692.
27. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression. Pediatr Nephrol. 2005;20:811-813.
28. Bakkaloǧlu A. Lupus nephropathy in children. Nephrol Dial Transplant. 2001;16 (Suppl. 6):126-128.
29. Singh S, Devidayal, Kumar L, Joshi K. Mortality patterns in childhood lupus - 10 years' experience in a developing country. Clin Rheumatol. 2002;21:462-465.
30. Bakr A. Epidemiology treatment and outcome of childhood systemic lupus erythematosus in Egypt. Pediatr Nephrol. 2005;20:1081-1086.
31. Sumboonnanonda A, Vongjirad A, Suntornpoch V, Laohapand T, Parichatikanond P. Renal pathology and long-term outcome in childhood SLE. J Med Assoc Thai. 1998;81:830-834.
32. Hagelberg S, Lee Y, Bargman J, et al. Long-term follow-up of childhood lupus nephritis. J Rheumatol. 2002;29:2635-2642.
33. Emre S, Bilge I, Sirin A, et al. Lupus nephritis in children: Prognostic significance of clinicopathological findings. Nephron. 2001;87:118-126.
34. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: A single center's experience. Pediatr Nephrol. 2007;22:222-231.
35. Askenazi D, Myones B, Kamdar A, et al. Outcomes of children with proliferative lupus nephritis: The role of protocole renal biopsy. Pediatr Nephrol. 2007;22:981-986.
36. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: The role of socioeconomic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039-2046.
37. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad longterm renal outcome in lupus nephritis. Kidney Int. 1996;50:2047-2053.
38. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: A longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924-929.
39. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-424.
40. Carlavilla A, Gutierrez E, Ortuno T, Morales E, Gonzalez E, Praga M. Relapse of lupus nephritis more than 10 years after complete remission. Nephrol Dial Transplant. 2005;20:1994-1998.